Sign in

    Laura Suriel • Alliance Global Partners

    Laura Suriel is an Equity Research Associate at Alliance Global Partners, focusing primarily on the healthcare and biotechnology sectors. She provides coverage for companies such as GeoVax Labs and INmune Bio, participating in earnings calls and delivering research insights to institutional clients. Her career began after graduating from Fairleigh Dickinson University, and she has been with Alliance Global Partners since at least 2024, having worked closely with senior analysts on key coverage areas. Suriel holds a strong academic foundation but lacks publicly disclosed FINRA registrations or major securities licenses, and has not been featured in performance rankings or notable industry recognitions to date.

    Laura Suriel's questions to Imunon Inc (IMNN) leadership

    Laura Suriel's questions to Imunon Inc (IMNN) leadership • Q1 2025

    Question

    Asked about the company's manufacturing and inventory readiness for the OVATION 3 trial. Also requested a status update on the collaborative trial with the Break Through Cancer Foundation and whether preliminary results are still expected by year-end.

    Answer

    The company has brought manufacturing in-house and has sufficient product ready for the OVATION 3 trial. The trial with the Break Through Cancer Foundation has initiated a new site, is seeing progress at other sites like Johns Hopkins, and is still on track to report data by the end of the year.

    Ask Fintool Equity Research AI

    Laura Suriel's questions to INmune Bio Inc (INMB) leadership

    Laura Suriel's questions to INmune Bio Inc (INMB) leadership • Q1 2025

    Question

    Laura Suriel, on behalf of Alliance Global Partners, asked for an update on the CORDStrom program, specifically the timeline for the open-label trial and U.S. enrollment plans. She also inquired about the regulatory landscape for RDEB treatment, particularly in light of Abeona's recent gene therapy approval.

    Answer

    CSO Dr. Mark Lowdell clarified that the BLA filing for CORDStrom, planned for 2026, will be based on existing data from the U.K. trial and is not dependent on a new U.S. study. An IND for a U.S. follow-on trial will be submitted later this year. Regarding the competitive landscape, Dr. Lowdell positioned CORDStrom as a systemic therapy for a systemic disease, contrasting it with Abeona's topical product. He emphasized that CORDStrom addresses widespread symptoms beyond the skin, creating a distinct and complementary market opportunity.

    Ask Fintool Equity Research AI

    Laura Suriel's questions to GeoVax Labs Inc (GOVX) leadership

    Laura Suriel's questions to GeoVax Labs Inc (GOVX) leadership • Q4 2024

    Question

    Laura Suriel, on for James Molloy at Alliance Global Partners, asked for an update on data readout timelines for the two Phase 2 trials of CM04S1 in immunocompromised patients and questioned how potential government funding pullbacks might impact the BARDA Project NextGen trial.

    Answer

    Dr. Kelly McKee responded that readouts for the cell transplant patient study are expected in early-to-mid 2026, while the CLL study is hoped to be fully enrolled by year-end, with interim data presentations coming. Executive David Dodd addressed the funding question, stating that communications with BARDA remain positive and are 'business as usual,' with a directive to prepare for a Q4 trial start. He emphasized that GeoVax's vaccine was selected for its potential for broad, durable protection, a key goal of the NextGen program.

    Ask Fintool Equity Research AI

    Laura Suriel's questions to BioCardia Inc (BCDA) leadership

    Laura Suriel's questions to BioCardia Inc (BCDA) leadership • Q2 2024

    Question

    Laura Suriel, on behalf of James Molloy at Alliance Global Partners, asked for an update on the submission process for CardiAMP approval in Japan and whether approval is still anticipated next year. She also inquired about the status of the collaboration with CellProthera following its recent Phase II trial and the potential timeline for a subsequent Phase III study.

    Answer

    Peter Altman, Ph.D., President and CEO, detailed the ongoing process with Japan's PMDA, stating the next step is a general consultation before a potential clinical consultation using the final Heart Failure I data. He expressed confidence in their position, citing the large patient dataset, existing Japanese approval for their cell processing platform, and U.S. reimbursement data as supportive factors. Regarding CellProthera, Dr. Altman emphasized BioCardia's role as a supportive partner providing its efficient delivery system, but stated that CellProthera is responsible for determining its own future regulatory and strategic pathways, and BioCardia respects its partner's autonomy in sharing those plans.

    Ask Fintool Equity Research AI

    Laura Suriel's questions to BioCardia Inc (BCDA) leadership • Q2 2024

    Question

    Inquired about the status and timeline for CardiAMP approval in Japan and the progress of the CellProthera collaboration, including potential Phase III trial timelines.

    Answer

    The executive detailed the ongoing process with Japan's PMDA, highlighting the critical importance of the final Heart Failure I data. He expressed optimism for approval based on several factors. Regarding CellProthera, he confirmed the collaboration is strong but deferred to the partner for announcements on their future trial and regulatory strategy.

    Ask Fintool Equity Research AI